Non-Small Cell Lung Cancer Clinical Trial

TITLE:
A Phase 1/2 Study of XL 184 With or Without Erlotinib in Subjects With Non-small Cell Lung Cancer

PURPOSE:
To evaluate the safety and tolerability of XL-184 in combination with erlotinib.

PHASE:
1/2

INSTITUTIONAL REVIEW BOARD:
Sterling

STATUS:
Closed

ELIGIBILITY:
Adults aged 18 years or older with histologically or cytologically confirmed unresectable stage IIIb/IV non-small cell lung carcinoma with a life expectancy >3 months.

DURATION:
24 months

Principal Investigator:
Michael B. Wax, MD

CONTACT:
Isabella Rodrigues, PhD
Clinical Research Coordinator
908-277-8630